Tracking Innovation in New Molecular Entities of 2013
A review of this year's crop of the new molecular entities and new biologics license applications approved by FDA thus far in 2013.

Opioid Regulation Challenges FDA and Manufacturers
New policies and products seek to maintain access to pain medicines while curbing rampant abuse.

Advertisement: Pharmaceutical Technology editorial staff proudly introduces PharmTech TV, their latest high quality pertinent content in a brand new industry-breaking format.Tune In Now

Biotechnology Innovation and Growth in Israel
Israel's diverse population, high-quality healthcare system, and resilience to global financial stress make it a strong partner for R&D, clinical research, and market growth.

Bristol-Myers Squibb to Sell Diabetes Business to AstraZeneca
Bristol-Myers Squibb agrees to sell global diabetes business to AstraZeneca for $2.7 billion upfront plus an addition $1.4 billion in potential regulatory- and sales-based milestone payments.

Advertisement: Optimizing CMO Selection for High-Potency Pharmaceutical Product Development and Manufacturing Wednesday, January 8, 2014 at 10:00 AM - 11:00 AM Eastern Standard Time (EST) and Wednesday, January 15, 2014 at 10:00 AM - 11:00 AM Central European Time (CET) Register Free at: www.pharmtech.com/highlypotent

MedImmune Collaborates with Johns Hopkins University
AstraZeneca's MedImmune will collaborate with Johns Hopkins University in both biologics and small-molecule projects.

Biogen Idec, Samsung Bioepis Target Anti-TNF Biosimilars in Europe
Biogen and Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, advance plans for anti-TNF biosimilar product candidates.

FDA and European Medicines Agency Announce Generic-Drug Application Inspections Initiative
FDA and EMA launch initiative to share bioequivalence inspection information.

AstraZeneca Issues Statement on Competitor to Nexium
AstraZeneca issues a statement regarding the launch of esomeprazole strontium in the United States.

Pfizer, Teva Settle Patent Litigation on Viagra
Pfizer settles its litigation against Teva Pharmaceuticals regarding Pfizer's patent covering the use of Viagra.

Bridgepoint Development Capital Acquires Quotient Clinical
Bridgepoint Development Capital acquires Quotient for an undisclosed sum.

Accelrys Acquires Qumas
Accelrys acquires Ireland-based Qumas, a provider of cloud-based and on-premises enterprise compliance software.